Boehringer Ingelheim Launches New SGLT-2 Inhibitor Esgliteo

Boehringer Ingelheim has launched Esgliteo (empagliflozin/linagliptin), a compound therapy of the SGLT-2 inhibitor Jardiance (empagliflozin) and the DPP-4 inhibitor Trajenta (linagliptin).

Esgliteo is its smaller tablet size, measuring approximately 8.1 millimetres. This size is intended to enhance convenience for patients who struggle with swallowing larger pills. Additionally, Esgliteo offers two dosage options to cater to patients in need of additional glycaemic control: 10 mg of empagliflozin combined with 5 mg of linagliptin, or 25 mg of empagliflozin with 5 mg of linagliptin.

Esgliteo brings several benefits as a combination therapy. Firstly, it delivers a superior glucose-lowering effect compared to either medication used alone. In the EMPA-REG OUTCOME study, empagliflozin, the SGLT-2 inhibitor component, demonstrated a significant cardiovascular benefit by reducing the risk of major cardiovascular events (cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke) by 14% compared to a placebo.

Esgliteo harnesses the complementary mechanisms of SGLT-2 and DPP-4 inhibitors to achieve enhanced glucose control. In a phase 3 study, Esgliteo exhibited improved glycemic control at week 24 when compared to using empagliflozin or linagliptin alone as monotherapies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!